Thanks for the info. I tried going to the Kamada website (www.kamada.com/?) but it seems down. I take it Kamada's is recombinant too. Can't PLX avoid first to market Orphan's . The idea of being able to drink a glass of carrot juice to get your Enzyme instead of an IV sounds interesting. I have to take a closer look to see if they get good up-take or if they degrade before researching their targets. At $5 and now with Gaucher revenue though I imagine they still have a burn the market cap doesn't seem too bad if their pipeline is promising.